Slide 1: Exchange filing cover letter
RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli , Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email : info@rpglifesciences.com ~ LIFE SCIENCES www.rpglifesciences.com CIN: L24232MH2007PLC169354 July 27, 2024 To, The Manager BSE Limited L
Slide 2: Investors' Presentation Q1 FY25
R?Ci LIFE SCIENCES An ~>>R~G Company Investors' Presentation Ql FV25
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: One of India's fastest-growing diversified conglomerates
RPG Group: One of India's fastest-growing diversified conglomerates IUNLEASHTALENT RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses TOUCH LIVES in Infrastructure, Technology,
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company APls to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global g
Slide 6: RPG Life Sciences: Product Portfolio
RPG Life Sciences: Product Portfolio Strong 'Textbook' brands; 1' Chronic and Specialty therapies Key Therapies OF Key Products Legacy Portfolio New Portfolio Nephrology lmmunosuppressants Textbook Brands Specialty Chronic Rheumatology (Existing Products} }I~r1'fali( SacuNew~~ Azoran· Trastuzumab 5a
Slide 7: An <>» R?G Company
6 An <>» R?G Company R?G LIFE SCIENCES
Slide 8: Journey of RPG Life Sciences
Journey of RPG Life Sciences • Process Excellence Product Portfolio, People, Business Processes ----.L.s.......-.... Fundamentals Fixation Sales Hygiene, People, Organization Sustainable Profitable Growth Revenues, Volumes, Margins Benchmark Performance Profitability, Leverage, Liquidity Ratios Scal
Slide 9: Building a Strong-Consistent-Profitable Business
Building a Strong-Consistent-Profitable Business An <>» R?G Company R?G LIFE SCIENCES
Slide 10: Driving Transformation Agenda
Driving Transformation Agenda Tenet 1 Propel growth of DF Business Tenet 2 Accelerate Migration to Higher Margins Tenet 3 Build Strategic Assets/ Footprints Tenet 4 Accelerate IF Business Tenet 5 Embrace Digitalisation to transform Business Tenet 6 Strengthen organization to deliver core strategy An
Slide 11: Focussing on Execution
Focussing on Execution Multiple Projects targeted to Transform Business, ~ Costs, 1' Quality, Add New Business ■ Comprehensive Business Transformation Project ■ Innovation Projects ■ Plants Infra Modernization-Capacity Expansion Projects ■ Digitalization Projects ■ COGs Reduction Projects ■ M&A Proj
Slide 12: Upticking Growth Trajectory
Upticking Growth Trajectory Bold Move 1 Galvanizing Organization to an "Inspiring Purpose": Framing and embedding in the organisation Bold Move 2 "Small Brands" to Building "Mega Brand of 100 er+; future 500 er OTC": Naprosyn Bold Move 3 "Small Product" to Building "Mega Rx Portfolio of 100 er +; Po
Slide 13: Energizing Happy Teams: Happiness Framework
Energizing Happy Teams: Happiness Framework Peo le Initiatives for a Building Ha Performance focussed Culture I Love My Work .... I Feel Valued @ RPGLS Heroes Outperforma nee recognition I am Growing We Skill. You Grow. Competency building -< ( ?rl ~ You Excel. We Applaud. continuum i~'I l'.J Motiva
Slide 14: Product Lifecycle Management - Naprosyn
GIi m pses of Actions Product Lifecycle Management- Naprosyn LCM Strategy LCM Application to Legacy Brand - Naprosyn New Strengths ,i ~Naprosyn® Naproxen 125 mg I 5 ml Suspension Naproxen Sodium Tablet USP 275 mg I 550 mg New Dosage Forms New Molecule Combinations & Naprosyn® SR NaprosyJ!+~ Naproxen
Slide 15: Sales and Marketing: Digitalization - RPG Serv
Glimpses of Actions: Sales and Marketing: Digitalization- RPG Serv RPG Serv: Anytime Anywhere Doctor Support Initiative 10 versions launched across 10 diverse CardioCare 451PM::.'- D , .~~c::J, NephroCare Customer segments X j rpgser, rpgl fesc ,ences com < ; • Welcome DrMangesh Im Search DiabetoCar
Slide 16: Sales and Marketing: AI at RPGLS
Glimpses of Actions: Sales and Marketing : Al at RPGLS- LSAI Gen AJ for Physician Se:rv"'ces itiem .A t for .C ampaign Dashboards .J.1 r-: .. , .... I - 1~11 T l.i l.J'h 1-:: I /, 'I I, '!1"l-.1 t ••II"- ■1 11 -t li •.-,• 1 ~ p ,~;;Cll'ff;rud:tll] ..--;:j ' • u[Pc'O!iklttml - - M - - - 0 ,I; I,... •
Slide 17: Manufacturing and Quality: Digitalization
GIi m pses of Actions Manufacturing and Quality: Digitalization across Manufacturing Functions Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation • Operates Pumps • Safe, reliable, Sc
Slide 18: Sustainability - ESG Initiatives FY24
Glimpses of Actions Sustainability- ESG Initiatives FY24 • Carbon emission reduction ~15% (FY23); ~26.8% (FY24) Environmental • Energy Efficiency: Energy Efficient pumps ; Leakages rectification of compressed air system; High Efficiency 1'8% (FY23); 1'26.0 % (FY24) chillers/Brine Plant ~7% (FY23); ~
Slide 19: HR: Monthly Townhalls
GIi mpses of Actions HR: Monthly Townhalls (,__-~ 1 Hello Happiness Forums: Monthly Town hall for Connect, Recognition and Camaraderie I hello happiness _ I i An <>» R?G Company R?G LIFE SCIENCES
Slide 20: HR: Employee Development, Motivation and Engagement
GIi mpses of Actions HR: Employee Development, Motivation and Engagement 1Rev.rairdls & Re.c:ognitiom Hi-Fniie.- Fu111ctio111 ( Employee Motivation: Happy C:an:1$ and Emaileirs " •• V -'--- An <>» R?G Company R?G LIFE SCIENCES
Slide 21: An <>» R?G Company
20 An <>» R?G Company R?G LIFE SCIENCES
Slide 22: Q1 FY25 Financials: Strong All-Round Performance
Ql FV25 Financials: Strong All-Round performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operationsf EBITDA & EBITDA Margin PBT & PBT Margin 147.8 pr 165.4 41.4 29.8 34.1 ~ Ql FY24 Ql FV25 Ql FY24 B Ql FY25 Ql FY24 Ql FV25 PAT & PAT Margin f EPS f 26.8 Ql FY24 Ql FV25 Ql FY24 Ql F
Slide 23: Key Financials Yearly Trends
Key Financials Yearly Trends An Un-interrupted Upward Trajectory Continues Unabated (All figures in Rs. Crores except EPS in Rs.) Revenue from Operationsf EBITDA & EBITDA Margin t PBT & PBT Margin t 135.4 117.8 582.1 107.5 512.8 89.4 91.7 440.2 73.2 375.6 389.1 70.8 59.9 53.6 FY20 FY21 I FY22 FY23 1
Slide 24: Margins Yearly Trends - at a glance
Margins Yearly Trends- at a glance An Uninterrupted Upward Trajectory continues- EBITDA crosses 25% despite market challenges EBITDA% 25.1% 21.8% PAT% 16.2% 9.8% ~ % 8.7% ~ 6.~0% Z2;0_ _ _ _..... 5.9% 4.2% 4.7% 3.9% 3.9% 3.3% 0.5% ,y' ~ ◊ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 23 An <>» R?G Company R?G LIFE SCIENCES
Slide 25: Key Financial Ratios Yearly Trends
Key Financial Ratios Yearly Trends {ROCE, ROE, D/E) Upward Trajectory continues ROCE% l ROE%f Debt/Equity Ratio ! 29 70/ 31.0% 28.5% • /O 22.0% 23.4% 24.9% 20.1% 0.22 18.5% 20.9% 16.4% 0.06 - 9.7% 0.01 6.7% 0.00 0.00 0.00 I FY19 FY20 FY21 FY22 FY23 FY24 I FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21
Slide 26: Q1 FY25: Business Segment-wise Performance
Ql FV25: Business Segment-wise Performance Healthy double-digit growth in all business segments Domestic Formulations contributed 65% to total sales of Q1FV25 • 10% sales growth driven by both Legacy and New products • Growth consistently higher than the market Business Segments • New products* cont
Slide 27: ICRA Rating Upgradation in FY24
RPG Life Sciences ICRA Rating Upgradation in FV24 A- (FY19) to A (FY21) to A+ (FY24) Long term rating recently upgraded to A+ from A Short term rating reaffirmed at A1 Outlook on long-term rating has been retained as Stable The rating upgradation factors: • Strong brands in the Indian Pharmaceutical
Slide 28: An <>» R?G Company
27 An <>» R?G Company R?G LIFE SCIENCES
Slide 29: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Textbook Brands - Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in lmmunosuppressant category • Good Customer Coverage - Cardiolo
Slide 30: International Formulations (IF) Business: Overview and Strategy
International Formulations {IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 31: APIs Business: Business Strategy and Way Forward
APls Business: Business Strategy and Way Forward • High value, low volume, niche APls • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus - long-l
Slide 32: Infrastructure & Backend Capabilities
Infrastructure & Backend Ca abilities 31 An <>» R?G Company R?G LIFE SCIENCES
Slide 33: Manufacturing Facilities
Manufacturing Facilities • Fl unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved • Modernization cum Capacity Expansion underway • F2 unit caters to the regulate
Slide 34: Strong Backend Capabilities
Strong Backend Capabilities 00 • Formulations R&D In addition to Formulations Development of IR, have capabilities to develop modified release & complex , ~ _ ✓ • i Di italisation Focus Areas • Quality Management systems: e-QMS, e-DMS, e-LMS. • Access to critical manufacturing equipment through IRIS
Slide 35: An <>» R?G Company
34 An <>» R?G Company R?G LIFE SCIENCES
Slide 36: RPG Life Sciences recognized as India's Top Value Creators by Dun & Bradstreet
RPG Life Sciences recognized as India's Top 500 Value Creators by Dun & Bradstreet eQ-(l r,ity~ r:!PG lite Sder.,c.-s Limit d h 1 ~ f • ur.-d ,11
Slide 37: Jamnalal Bajaj Award for Fair Business Practices
RPG Life Sciences Awarded with 'Jamnalal Bajaj Award for Fair Business Practices' An <>» R?G Company R?G LIFE SCIENCES
Slide 38: RPG Life Sciences Bagged Top Awards of the Industry
RPG Life Sciences Bagged Top Awards of the Industry An <>» R?G Company R?G LIFE SCIENCES
Slide 39: Naprosyn+ bags Brand Award
New Launch Naprosyn+ bags Brand Award u ,SILVERIM Naprosyn+ An <>» R?G Company R?G LIFE SCIENCES
Slide 40: An <>» R?G Company
39 An <>» R?G Company R?G LIFE SCIENCES
Slide 41: Transformation Agenda will continue to drive All-Round Performance
Transformation Agenda will continue to drive All-Round Performance Profit Growth and Focus on Revenue Growth Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measures both in Opex Fram
Slide 42: 7 Pillars identified to Scale-up business
Diligent work on the Comprehensive 7 Pillars identified to Scale-up" business 1 2 7 State-of-a rt Targeted Talent Institutionalized TECHNOLOGY 1' Capacity Niche- focus enablement Development INNOVATION PLANTS R&D PIPELINE /Acquisition • Focused New • lnstitutionalizat • Technology • M&A • Identify &
Slide 43: 0«1»000 0(:)G An <>» R?G Company
0«1»000 0(:)G An <>» R?G Company _ _ _ _ _ _ _ _ _ R?G L1FEsc1ENces